 CAMBRIDGE, Mass.--BUSINESS WIRE--Gemini Therapeutics, Inc. Nasdaq:GMTX, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration AMD, today announced initial data from its Phase 2a ReGAtta study of GEM103 as of May 2021 in patients with geographic atrophy GA secondary to dry AMD. ReGAtta is a dose escalation trial of GEM103, which is intravitreally administered recombinant human complement factor H CFH, in dr 